CLVT — Clarivate Plc · 2026-09-05 · Verdict: WATCH · Conviction 3

Price $2.07 (screen row, universe_under2b.csv dated 2026-09-05; no live prices available) · Mkt cap $1.324B · EV $5.316B · EV/EBIT 74.3x (screen, on CY2025 GAAP EBIT) · FCF yield 27.6% · Net debt $(3.99)B · ADV $7.4M Sources read: 10-K 2026-02-24 (Items 1, 1A, 7), 10-Q 2026-07-29, DEF 14A 2026-04-01, 8-Ks 2026-05-18, 2026-06-08, 2026-07-06 (x2), 2026-07-29 (x2) including the Q2 release and both investor decks, Form 4s (12m). No transcript in the pack.

1. What the business actually does

Clarivate sells subscription data, workflow software and expert services to three customer sets: academic and government institutions (Web of Science, ProQuest, the Alma library platform), intellectual property owners (Derwent, CompuMark, patent and trademark renewal services), and life sciences companies (Cortellis, DRG). It serves more than 45,000 customers, and roughly 83% of 2025 revenue was subscription or re-occurring (10-K 2025, Item 1A), with a 92.5% annual renewal rate for 2025 (10-K 2025, Item 7). On 2026-07-03 it agreed to sell the Life Sciences and Healthcare segment to Altaris for $600M (8-K 2026-07-06), leaving a two-segment company of roughly $1.99B revenue and ~$890M Adjusted EBITDA (LS&H deck, 2026-07-06, p12).

2. Why it is mispriced — the edge case

There is no identifiable edge case, and that caps the verdict at WATCH. No spin-off, no index event, no dated forced seller. Ownership is concentrated but nobody is being made to sell: Leonard Green 18.17%, Clarkston 11.24%, Exor 10.48%, Onex 6.67%, Castik 5.93% (DEF 14A 2026, Beneficial Ownership). Director Andrew Snyder sold 2,489,618 shares at $1.94 on 2026-08-03 for the CIG entities (Form 4, 2026-08-05), a third of one day's volume, not a dislocation.

What the screen gets wrong is the multiple, not the price. The 74.3x EV/EBIT is an artifact: CY2025 GAAP EBIT of $71.5M is struck after $757.2M of D&A, roughly $541M of which is amortization of acquired intangibles, against only $263.2M of capital spending (10-K 2025, Item 7; Q2 release reconciliations). The cash is real: $365.3M of free cash flow in 2025 and $357.5M in 2024 (10-K 2025, Item 7), with 2026 guided to $365M-$435M and the current indication at the low end (Q2 deck, 2026-07-29, p18).

The honest framing is a levered stub, not a hidden asset. Debt is 72% of enterprise value, so every dollar repaid becomes a dollar of equity if enterprise value holds. That is a mechanism, not a mispricing, and the market can see it.

3. Unit economics and growth

Revenue fell 4.0% in 2025 to $2,455.2M, organic -0.1% (10-K 2025, Item 7). H1 2026 revenue of $1,172.8M was -3.5%, organic -0.4%, with organic recurring +0.7% offset by organic transactional -9.4%; Q2 organic transactional was -15.7%, partly deliberate as customers migrate to subscriptions (Q2 release, 2026-07-29). Segment organic growth splits the company: A&G +1.6% in 2025 and +1.2% in H1 2026, IP -1.9% and -1.8%. IP is about a third of the retained business and is shrinking.

Margins hold. Adjusted EBITDA margin was 42.1% in Q2 both years and rose 90bps to 41.6% in H1. But absolute Adjusted EBITDA has fallen three straight years: $1,117.2M (2023), $1,060.4M (2024), $1,001.8M (2025) (DEF 14A 2026, Pay versus Performance). Capex has been cut from $289.1M in 2024 to $263.2M in 2025 to a guided ~$245M in 2026, which is how free cash flow stays flat while profit falls. Capex is capitalized product and content development, close to maintenance spend, and still runs slightly above non-acquisition D&A of roughly $219M, so the free cash flow is not flattered by underinvestment in any obvious way.

4. Balance sheet and capital allocation

Total debt was $4,251.5M at 30 June 2026 against $217.7M of cash, down $218.4M year on year after a $100M January redemption and $117.6M of open-market note repurchases at about a 6% discount to par (Q2 release). Maturities are the 2028 and 2029 notes plus a term loan, with an undrawn $775M revolver and no near-term wall (LS&H deck, p13). Management plans ~$900M of 2026 repayment: $211M done, ~$200M from H2 free cash flow, ~$500M from Altaris proceeds, taking net leverage from 4.0x toward ~3.5x (Q2 deck, p21).

Buybacks have stopped: $225M in 2025, only $18.1M in H1 2026, ~$20M guided for the year, against $275.5M still authorised through 2026-12-31 (10-K 2025, Item 7; Q2 deck, p21). Holders are paid in deleveraging, not shares. Over twelve months the Form 4s show $1.67M of open-market buying, all by director Kenneth Cornick at $1.86 and $1.85 on 2026-08-06 and 2026-08-07, against Snyder's $4.83M of selling three days earlier.

5. Management: what they said versus what they did

The five-year record is the problem. $100 invested at the start of the pay-versus-performance window was worth $11.24 at end-2025 against $134.41 for the peer group, with net losses in all five years (DEF 14A 2026). Turnover is heavy: the CEO changed in 2024, the IP president departed 2026-06-09 (8-K 2026-06-08), and CFO Jonathan Collins resigned 2026-07-24 effective 2026-08-07, replaced by the internal chief accounting officer (8-K 2026-07-29).

Management calls the Altaris deal "10x Adj. EBITDA less Capital Expenditures; 3x v. CLVT at 7x" (LS&H deck, p11). True only on the capex-adjusted metric, which flatters a segment management itself calls the most capital-intensive in the portfolio. On plain 2026 estimated EBITDA the segment sold for $600M against ~$120M, or 5.0x, versus the parent's own ~5.4x using the same footnote's $5.5B enterprise value and ~$1,010M. And only $500M is cash at close; $25M is deferred to January 2028 and $75M is an unsecured note from a private-equity buyer.

6. Valuation

Post-close, on the company's own bridge, year-end 2026 debt is roughly $3,523M against ~$254M cash, so net debt near $3,269M, with pro forma Adjusted EBITDA ~$890M and free cash flow ~$385M (LS&H deck, p12; Q2 deck, p21).

Base (50%): EBITDA flat at $890M, 6.0x, equity $2,146M, $3.35 per share. Bear (25%): AI substitution and continued IP decline take EBITDA to $800M at 4.5x, equity $406M, $0.63 per share. Leverage does the rest. Bull (25%): recurring growth reaches the guided 2%+, EBITDA $940M at 7.5x, equity $3,856M, $6.03 per share. Probability-weighted $3.34, about 61% above $2.07, with a bear case 70% below it.

Reverse DCF: at a 10% weighted cost of capital, the pro forma enterprise value of about $4.59B against roughly $630M of unlevered free cash flow implies the retained business shrinks about 3.7% a year forever, against actual organic revenue of -0.4% and organic recurring of +0.7% in H1.

7. Catalysts and timeline

Q3 2026 results, the first with LS&H in discontinued operations and the first test of the promised H2 acceleration. Close of the Altaris sale, guided by year end, outside date 2027-03-03 with a $33M reverse fee (8-K 2026-07-06). Retirement of ~$700M of 2028 and 2029 notes in H2.

8. Risks and pre-registered kill criteria

Risks: free or cheap AI substitutes for curated information, which the 10-K names directly (Item 1A); reduced government research funding, which the 10-K says already happened in 2025; and 3.7x leverage that turns a modest EBITDA miss into a large equity loss. 1. Organic recurring revenue growth below 1.5% in either Q3 or Q4 2026. The full-year guide of ~1.5% against H1 actual of 0.7% requires roughly 2.3% in H2, from 0.5% in Q2. 2. Full-year 2026 free cash flow below $340M, or H2 free cash flow below $200M against the $242M the low end of guidance requires. 3. The Altaris agreement terminates, or closes for less than $450M of cash at closing. 4. Net leverage above 3.5x at any quarter end after the transaction closes.

9. Verdict and one-paragraph summary

WATCH, conviction 3. Clarivate throws off $365M to $400M of genuine free cash flow against a $1.32B market value, a 28% equity yield, and all of it now goes to retiring debt that is 72% of enterprise value, so flat profits alone would compound equity at roughly 29% a year; the screen's 74x EV/EBIT is an artifact of $541M of annual acquired-intangible amortization against $263M of capex, and the cash is not an artifact. But there is no edge case to underwrite, no forced seller, no spin, no index event, just a controversial levered information business any investor can see, and the price already implies only a 3.7% perpetual decline, which is not obviously wrong given Adjusted EBITDA has fallen three years running, the IP segment shrank 1.8% organically in H1, five-year total shareholder return is $11 against $134 for the peer group, and the CFO, the IP president and the chief accounting officer have all changed in the last three months. The decisive question is dated and checkable: management's own full-year guide requires organic recurring growth of roughly 2.3% in H2 after printing 0.5% in Q2, and organic ACV growth has decelerated two quarters running to 1.5% against a 2.0% to 3.0% guide. Q3 answers it.

Research for discussion, not investment advice. Positions and sizing are the reader's decision.